Get the Stockscreener App
29.64
0.25%
-0.095
Travere Therapeutics Inc stock is traded at $29.64, with a volume of 593.06K.
It is down -0.25% in the last 24 hours and down -16.13% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$29.73
Open:
$29.66
24h Volume:
593.06K
Relative Volume:
0.27
Market Cap:
$2.65B
Revenue:
$333.87M
Net Income/Loss:
$-169.00M
P/E Ratio:
-14.53
EPS:
-2.04
Net Cash Flow:
$-157.30M
1W Performance:
+6.40%
1M Performance:
-16.13%
6M Performance:
+83.85%
1Y Performance:
+42.50%
1-Day Range:
$29.07
$30.16
1-Week Range:
$26.78
$30.16
52-Week Range:
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
29.64 | 2.66B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Emerald Mutual Fund Advisers Trust Buys 59,514 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
How liquid is Travere Therapeutics Inc. stockPortfolio Performance Report & Consistent Profit Trade Alerts - mfd.ru
BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari - Insider Monkey
Emerald Advisers LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
14 Best Mid-Cap Growth Stocks to Buy Right Now - Insider Monkey
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells $273,400.00 in Stock - MarketBeat
Is Travere Therapeutics Inc Gaining or Losing Market Support? - Benzinga
Top 3 Health Care Stocks That Could Blast Off This Month - Benzinga
Merger Talk: Whats the analyst consensus on SDOWEarnings Overview Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Travere Therapeutics Stock Climbs After FDA Eases FILSPARI Monitoring Requirements - MSN
Travere therapeutics CFO sells $104,463 in stock - MSN
Stephens Investment Management Group LLC Purchases Shares of 1,599,668 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics : Investor Fact Sheet - marketscreener.com
Rate Hike: Is Travere Therapeutics Inc stock heavily shortedMarket Trend Review & Low Risk Entry Point Guides - baoquankhu1.vn
Chipmakers Recap: Whats the MACD signal for Travere Therapeutics IncMarket Activity Report & Technical Confirmation Alerts - baoquankhu1.vn
Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses - TradingView — Track All Markets
Two Biotechs to Play in Uncertain Times - TheStreet Pro
First Week of September 18th Options Trading For Travere Therapeutics (TVTX) - Nasdaq
TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm - Business Wire
Travere plummets as FDA extends Filspari review for rare kidney disorder - MSN
Equities Analysts Issue Forecasts for TVTX FY2030 Earnings - MarketBeat
Travere Therapeutics 2026 Outlook: Filspari Momentum, FSGS FDA Delay, And Market Potential - Seeking Alpha
Why Did TVTX Stock Crash 30% In Pre-Market Today? - Stocktwits
Travere, Ligand hammered on a surprise delay for their linchpin drug - MSN
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Travere Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation - ACCESS Newswire
Is Travere Therapeutics (TVTX) Pricing Reflect Long Term Value After Recent Share Price Pullback - Yahoo Finance
Travere Therapeutics (TVTX) Is Down 18.7% After FDA Extends FILSPARI FSGS Review Timeline – Has The Bull Case Changed? - Yahoo Finance
INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC - GlobeNewswire
(TVTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Travere stock rises as FDA extends Filspari review timeline - Investing.com
Travere stock rises as FDA extends Filspari review timeline By Investing.com - Investing.com UK
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
US FDA extends review of Travere’s drug for rare kidney disease - whtc.com
Biggest stock movers Wednesday: INTC, WRD, TVTX, and more (RIVN:NASDAQ) - Seeking Alpha
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS - BioSpace
Travere Therapeutics (TVTX) Suffers Significant Decline - GuruFocus
FDA extends review timeline for Travere’s FSGS drug application By Investing.com - Investing.com Nigeria
Travere Therapeutics Faces 15% Stock Drop Due to FDA Review Delay for Filspari - Intellectia AI
Why Travere Therapeutics Stock Got Trounced on Tuesday - Yahoo Finance
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - GlobeNewswire
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - GlobeNewswire Inc.
Travere Therapeutics provides corporate update and 2026 outlook - MSN
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS - FinancialContent
FDA Extends Review Timeline for Travere’s FILSPARI sNDA - TipRanks
Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug - Investor's Business Daily
Travere Therapeutics FDA Review Extension for FILSPARI - TradingView — Track All Markets
FDA pushes back Travere Therapeutics (NASDAQ: TVTX) FILSPARI FSGS decision date - Stock Titan
Travere shares fall as US FDA extends review of rare kidney disease drug - Reuters
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):